Billionaire Profile
M
Global Rank
#602

Image: Exposition nationale & coloniale de Rouen (1896 : Rouen, France) | Public domain | via Wikimedia Commons

Mathias Boehringer

CEO, Pharmaceuticals
GERMANY
Real-Time Net Worth
$6.636B
Estimated based on Pharmaceuticals stock value as of April 20, 2026
0% (24h)
Age
57
Source
Pharmaceuticals
Industry
Healthcare
Citizenship
GERMANY

Biography

Mathias Boehringer, a key figure in the pharmaceutical world, derives his wealth from Boehringer Ingelheim, the largest private pharmaceutical company globally. As of March 2026, his estimated net worth is $6.6 billion. He is part of the Boehringer/Von Baumbach family, who collectively control the company, which was founded in 1885. Boehringer Ingelheim is known for its research and development efforts, with a focus on respiratory diseases, metabolism, immunology, oncology, and central nervous system disorders. Mathias Boehringer, along with other family members, holds an equal share in the company, contributing to its long-standing success.

Fact Checked
Verified by Editorial Team
Live Data
Updated 4/20/2026

Wealth Over Time

In-Depth Profile

Early Life

Mathias Boehringer's early life details are not widely publicized, but his roots are firmly planted in the pharmaceutical legacy of the Boehringer family. The family's history dates back to 1885 when Albert Boehringer founded a small factory in Ingelheim am Rhein, Germany. This initial venture laid the foundation for what would become one of the world's largest pharmaceutical companies.

Rise to Success

Mathias Boehringer's rise is tied to the continuing success of Boehringer Ingelheim. The company has grown from a small factory to a global enterprise with a presence in 130 markets and over 54,500 employees. The company's growth is attributed to its focus on innovation, particularly in human and animal health. The family's commitment to maintaining the company's private status has allowed for a long-term focus on research and development.

Key Business Strategies

Boehringer Ingelheim's strategy centers on research and development, with significant investments in new therapies. In 2024, the company invested approximately €6.2 billion (approximately $6.7 billion) in R&D. Key therapeutic areas include cardiovascular, renal, metabolic, oncology, and respiratory diseases. The company also leverages partnerships and collaborations to expand its product pipeline. Furthermore, the family's long-term vision has enabled them to prioritize innovation over short-term financial gains.

Philanthropy

Information about Mathias Boehringer's specific philanthropic activities is not readily available in the search results. However, the Boehringer Ingelheim group is known for its commitment to improving the health of humans and animals, supporting research, and engaging in sustainable development.

Career Milestones

1885

Foundation of Boehringer Ingelheim

Albert Boehringer founded a small tartaric acid factory in Ingelheim am Rhein, Germany, which became the cornerstone of the family's pharmaceutical enterprise.

2017

Business Swap with Sanofi

Boehringer Ingelheim and Sanofi signed a business swap. Boehringer Ingelheim acquired Merial, the Animal Health subsidiary of Sanofi.

2024

Revenue

Boehringer Ingelheim generated revenue of EUR 26.8 billion (approximately $29 billion).

Philanthropy & Social Impact

Category

REAL initiative

$XB

REAL description

Business Philosophy & Leadership

Notable Quotes

"REAL quote"

Leadership Principles

REAL principle

REAL description

Controversies & Challenges

YEAR

REAL controversy

REAL description